drugset / Trial / NCT02249247

Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease

NCT02249247

Phase 2 Completed 577 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate the effect of 12-week treatment with three doses (5, 25 and 75 mg) BIIL 284 BS on exercise endurance, lung function, quality of life, spontaneous sputum and safety in patients with chronic obstructive pulmonary disease (COPD)

Timeline

Start
2001-04
Primary completion
2002-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject AMELUBANT Small molecule 5 mg
Subject AMELUBANT Small molecule 25 mg
Subject AMELUBANT Small molecule 75 mg